Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B; EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Panitch H, et al. J Neurol Sci. 2005 Dec 15;239(1):67-74. doi: 10.1016/j.jns.2005.08.003. Epub 2005 Sep 19. J Neurol Sci. 2005. PMID: 16169561 Clinical Trial.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group. Devonshire V, et al. Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Lancet Neurol. 2012. PMID: 22494956 Clinical Trial.
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Radue EW, et al. Arch Neurol. 2012 Oct;69(10):1259-69. doi: 10.1001/archneurol.2012.1051. Arch Neurol. 2012. PMID: 22751847 Clinical Trial.
Interleukin 17F level and interferon β response in patients with multiple sclerosis.
Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C. Hartung HP, et al. JAMA Neurol. 2013 Aug;70(8):1017-21. doi: 10.1001/jamaneurol.2013.192. JAMA Neurol. 2013. PMID: 23732754 Free PMC article. Clinical Trial.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group. Vermersch P, et al. Mult Scler. 2014 May;20(6):705-16. doi: 10.1177/1352458513507821. Epub 2013 Oct 14. Mult Scler. 2014. PMID: 24126064 Free article. Clinical Trial.
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C. Hartung HP, et al. J Neurol. 2015 Nov;262(11):2466-71. doi: 10.1007/s00415-015-7862-9. Epub 2015 Aug 5. J Neurol. 2015. PMID: 26239222 Free PMC article.
2,427 results